Media headlines about Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novelion Therapeutics earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.6172572827673 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

A number of equities research analysts recently weighed in on NVLN shares. Zacks Investment Research downgraded Novelion Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 17th. Royal Bank of Canada decreased their price target on Novelion Therapeutics from $9.00 to $8.00 and set a “sector perform” rating for the company in a research note on Friday, November 10th.

Novelion Therapeutics (NASDAQ NVLN) traded down $0.08 during trading on Friday, reaching $3.87. The company’s stock had a trading volume of 18,500 shares, compared to its average volume of 51,225. The company has a debt-to-equity ratio of 6.53, a quick ratio of 1.28 and a current ratio of 1.45. Novelion Therapeutics has a 52 week low of $3.08 and a 52 week high of $12.12. The stock has a market capitalization of $73.68, a PE ratio of -0.55 and a beta of 0.57.

Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.60). Novelion Therapeutics had a negative net margin of 108.10% and a negative return on equity of 57.36%. equities research analysts predict that Novelion Therapeutics will post -8.95 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Novelion Therapeutics (NVLN) Receiving Somewhat Favorable Press Coverage, Report Shows” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at

About Novelion Therapeutics

Novelion Therapeutics Inc, formerly QLT Inc, is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.

Insider Buying and Selling by Quarter for Novelion Therapeutics (NASDAQ:NVLN)

Receive News & Ratings for Novelion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics and related companies with's FREE daily email newsletter.